Fate Therapeutics FATE
NASDAQ FATE
$2.09 +0.03 (+1.58%)
As of: Oct 21, 2026 · 11:40 AM EDT

Fate Therapeutics (FATE) Convertible Debt (2013)

Updated

Fate Therapeutics (FATE) reported Convertible Debt of $23.7 million for Q3 2013.

Analysis

Fate Therapeutics (FATE) Convertible Debt (2013) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,130.22 Bn 1,098.81 Bn 19.71 Bn
2 Johnson & Johnson 613.62 Bn 532.15 Bn 17.26 Bn
3 AbbVie 501.46 Bn 474.57 Bn 12.70 Bn
4 Merck 366.84 Bn 321.22 Bn 12.21 Bn
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn
7 Amgen 235.39 Bn 190.79 Bn 7.24 Bn
8 Gilead Sciences 190.66 Bn 164.86 Bn 6.22 Bn
9 Pfizer 169.57 Bn 116.22 Bn 10.94 Bn
10 Fate Therapeutics 252.23 Mn 98.43 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2013 23.70 Mn
API Access

Fate Therapeutics Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=FATE&period=max&api_key=YOUR_API_KEY